首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials
【24h】

Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

机译:年轻高风险患者Myc / Bcl2双击淋巴瘤,Bcl2 +和/或发芽中心B细胞,如弥漫性大B细胞淋巴瘤,受益于剂量 - 致密化疗疗法,包括早期的CNS预防:来自北欧淋巴瘤组的数据分析 04和别致的试验

获取原文
获取原文并翻译 | 示例
           

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号